<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03570190</url>
  </required_header>
  <id_info>
    <org_study_id>Coordinate</org_study_id>
    <nct_id>NCT03570190</nct_id>
  </id_info>
  <brief_title>Registry to Evaluate the Impact of a Valve Coordinator on Aortic Stenosis / TAVI Outcome - (German Pilot)</brief_title>
  <acronym>Coordinate</acronym>
  <official_title>Registry to Evaluate the Impact of a Valve Coordinator on Aortic Stenosis / TAVI Outcome - (German Pilot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter registry in patients undergoing commercially available balloon
      expandable valve implantation. The registry will consist of 3 phases:

      Prospective determination of baseline Status Quo (3 months):

      Documentation of treatment pathways and endpoints of &quot;routine&quot; patients without educational
      program

      Dedicated reflection and training (1 day):

      One training session after the observational period to reflect on treatment pathways,
      exchange between valve coordinators involved, and develop improvements.

      Implementation of tailored changes (2 months):

      Implementation of the changes developed in the training.

      Determination of the effect (3 months):

      Coordinator measures optimization changes and determines effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Along the severe aortic stenosis (sAS) treatment pathway there are delays that may impact
      quality management and hospital efficiency. A dedicated valve coordinator, interfering with
      all stages of patient handling throughout the hospital may increase the efficiency of the sAS
      patient flow, accelerate decision making and clinical outcomes while at the same time
      decreasing resource consumption.

      The hypothesis is that the implementation of a dedicated valve coordinator will improve the
      patient flow of sAS patients scheduled to undergo TAVI, their outcome, patient and physician
      satisfaction and will optimize costs.

      In total, three centers across Germany (Munich, Düsseldorf, Bad Bevensen) will participate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Actual">December 19, 2019</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Evaluation of differences in length of stay (LoS)</measure>
    <time_frame>12 months</time_frame>
    <description>LoS in days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>30 days</time_frame>
    <description>According to VARC-2 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>30 days</time_frame>
    <description>Satisfaction score. The total score range is from 0 (extremely dissatisfied) to 40 (extremley satisfied).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Economic evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of early discharges in patients with sAS undergoing TAVI.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">161</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVI patients</arm_group_label>
    <description>elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coordinator</intervention_name>
    <description>A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:
Determination of the status quo
Dedicated reflection and training followed by implementation of tailored changes
Determination of the effect</description>
    <arm_group_label>TAVI patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive elective patients with a diagnosis of severe symptomatic aortic stenosis and
        admitted for TAVI attending one of the participating centers for commercially available
        balloon expandable valve implantation will be recruited.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective patients with a diagnosis of severe symptomatic aortic stenosis and admitted
             for TAVI

        Exclusion Criteria:

          -  patients not providing written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Bohmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz- u. Gefässzentrum Bad Bevensen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- u. Gefässzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <state>Niedersachsen</state>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <state>NRW</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

